NFJ Investment Group LLC grew its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 104.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 96,400 shares of the company's stock after purchasing an additional 49,176 shares during the period. NFJ Investment Group LLC owned about 0.18% of LivaNova worth $5,065,000 as of its most recent SEC filing.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Primecap Management Co. CA increased its holdings in LivaNova by 0.7% in the second quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company's stock worth $327,889,000 after buying an additional 44,049 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in LivaNova by 204.3% in the second quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company's stock worth $70,479,000 after buying an additional 863,157 shares during the last quarter. Victory Capital Management Inc. increased its holdings in LivaNova by 16.6% in the third quarter. Victory Capital Management Inc. now owns 935,102 shares of the company's stock worth $49,130,000 after buying an additional 133,401 shares during the last quarter. Magnetar Financial LLC increased its holdings in LivaNova by 8.1% in the second quarter. Magnetar Financial LLC now owns 814,452 shares of the company's stock worth $44,648,000 after buying an additional 61,114 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in LivaNova by 3.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company's stock worth $41,889,000 after buying an additional 25,277 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Analyst Upgrades and Downgrades
LIVN has been the topic of a number of research reports. Needham & Company LLC restated a "buy" rating and issued a $75.00 price objective on shares of LivaNova in a report on Monday, November 25th. The Goldman Sachs Group began coverage on LivaNova in a report on Friday, October 4th. They set a "buy" rating and a $65.00 price target on the stock. Mizuho lowered their price target on LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday, October 31st. Baird R W upgraded LivaNova from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 17th. Finally, StockNews.com downgraded LivaNova from a "strong-buy" rating to a "buy" rating in a report on Saturday, November 16th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $69.17.
View Our Latest Stock Analysis on LIVN
LivaNova Stock Performance
Shares of LIVN traded down $0.25 during mid-day trading on Wednesday, hitting $51.37. The company's stock had a trading volume of 200,398 shares, compared to its average volume of 607,427. The firm has a market capitalization of $2.79 billion, a PE ratio of 122.90 and a beta of 0.98. LivaNova PLC has a one year low of $42.75 and a one year high of $64.47. The stock's 50-day moving average is $52.29 and its two-hundred day moving average is $51.95. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.
About LivaNova
(
Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
See Also
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
